Enrollment on the Childhood Cancer Research Network (CCRN) of the Children's Oncology Group

NCT ID: NCT01117168

Last Updated: 2025-11-24

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Total Enrollment: 57816 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2010-04-30
• Study Completion Date: 2030-12-31

Brief Summary

The Children's Oncology Group has established a research network, the Childhood Cancer Research Network (CCRN), to collect information about children with cancer and other conditions that are benign but involve abnormal cell growth in order to help doctors and scientists better understand childhood cancer. The CCRN's goal is to collect clinical information about every child diagnosed with cancer and similar conditions in the United States and Canada, to allow researchers to study patterns, characteristics, and causes of childhood cancer. The information can also help researchers study the causes of childhood cancer. To expand the CCRN, parents of children who have been diagnosed with cancer will be asked to provide information about themselves and their child for research purposes.

Detailed Description

OBJECTIVES:

I. To obtain informed consent from parents of infants, children, adolescents, and young adults newly diagnosed with cancer (and their child when appropriate) to enter their names and certain information concerning their child into the Childhood Cancer Research Network and/or for permission to be contacted in the future to consider participating in future studies.

II. For children under the age of majority at the time of parental consent: Once the child reaches the age of majority, to obtain informed consent from that child to allow her/his name and other identifying information to continue to be available to the Childhood Cancer Research Network and/or to be possibly contacted in the future to consider participating in other studies.

OUTLINE:

Institutional membership in the Children's Oncology Group (COG) requires registration of all pediatric cancer patients seen at their site. This registration process includes all patients. In order to maximize the resource that a network would provide, it is necessary to have identifying information on a large proportion of the cases included within the network. Moreover, the resource would be further enhanced if informed consent from parents/patients was obtained to allow future contact regarding possible participation in non-therapeutic and prevention research.

Conditions

Pediatric Cancer; Leukemia; Sarcoma; Brain Tumors

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• All cancer cases with an ICD-O histologic behavior code of two "2" (carcinoma in situ) or three "3" (malignant).
• All lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant.
• The benign/borderline conditions which will be reportable by agreement shall include:
• Mesoblastic nephroma.
• All teratomas, regardless of locations.
• Myeloproliferative disease
• Langerhans Cell histiocytosis
• Patients with a secondary malignancy may be eligible provided they also meet the criteria in the above. These patients need to be enrolled using their primary diagnosis.
• Participants 0 through 21 years of age are eligible; irrespective of eligibility for other COG studies.
• Participant must be resident of the United States, Canada or Mexico.

• Maximum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

Children's Oncology Group

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Logan Spector

Role: STUDY_CHAIR

Susan Stork, CCRP

Role: STUDY_CHAIR

Locations

Children's Oncology Group

Arcadia, California, United States

Countries

United States

References

Ross JA, Severson RK, Pollock BH, Robison LL. Childhood cancer in the United States. A geographical analysis of cases from the Pediatric Cooperative Clinical Trials groups. Cancer. 1996 Jan 1;77(1):201-7. doi: 10.1002/(SICI)1097-0142(19960101)77:13.0.CO;2-7.

Reference Type: BACKGROUND

PMID: 8630931 (View on PubMed)

Other Identifiers

10-C-0111

Identifier Type: -

Identifier Source: secondary_id

100111

Identifier Type: OTHER

Identifier Source: secondary_id

ACCRN07

Identifier Type: -

Identifier Source: org_study_id

NCT00799253

Identifier Type: -

Identifier Source: nct_alias